Cancer marker and therapeutic target
US10261099B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 11, 2015 |
| Grant date | Apr 16, 2019 |
| Priority date | — |
| Expiry date | Aug 11, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/56
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Chemokine receptor CCR4 and its ligands CCL17 and CCL22 are used as markers for the identification and/or staging of cancer. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumour progression. CCR4, CCL17 and CCL22 are used as markers for the stratification of cancer patients according to their suitability for treatment with anti-cancer agents. Information of diagnostic character is provided by measuring the level of one or more of CCR4, CCL17 and CCL22 present in a patient sample. Methods of treatment of cancer patients which agents that modulate the activity of CCR4, CCL17 and CCL22. Methods of screening for agents which modulate the biological activities of CCR4, CCL17 and CCL22 provide anti-cancer agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.